Key Takeaways for Altria Group Stock as of July 2026
- Thirteen analysts rate Altria stock 4 buys, 7 holds, 1 underperform and 1 sell, and the 11 issuing price targets put the mean at just $71, barely below today’s $72.
- TIKR’s model targets $86 for Altria stock by December 2030, a 20% total return.
- Trading barely above that $71 consensus, Altria stock looks 20% undervalued against TIKR’s model, anchored in normalized EPS growth of 7% in Q1.
- But the FDA’s May 2026 policy could add 100 to 200 vape products fast, threatening the cigarette stabilization behind that EPS growth.
Altria Stock Nears Highs as Q1 EPS Grows 7.3% Under Outgoing CEO Gifford
Altria Group (NYSE: MO) grew adjusted diluted EPS 7.3% in the first quarter of 2026, a print that also closed out Billy Gifford’s tenure as CEO before his retirement. Altria stock closed at $72 on July 13, sitting just below its 52-week high of $75.
CFO Sal Mancuso, who now steers the business day to day, reaffirmed full-year adjusted EPS guidance of $5.56 to $5.72, a range that calls for growth of just 2.5% to 5.5% off last year’s $5.42 base even though Q1 alone outran that ceiling. Gifford framed the quarter directly on the call: “We delivered a strong start to the year, growing adjusted diluted EPS by 7.3% in the first quarter.” That framing leaves the back half of 2026 to absorb the deceleration management already expects.
That expected slowdown traces to a specific reversal. Adult smokers who had drifted into illicit flavored vapes are drifting back toward cigarettes as enforcement squeezes the unlicensed disposable market. Domestic cigarette shipment volume, adjusted for trade inventory swings, still fell 4% in the quarter, but that decline marked the fourth straight quarter of sequential improvement industrywide.
Marlboro captured 59.5% of the premium segment, up 0.2 points sequentially, while Basic’s targeted discount pricing added 2.4 share points in the value tier. Altria is defending its cigarette base on both ends of the price ladder at once, and that dual push is what let smokeable segment operating income grow 6.3% for the quarter.
Still, the enforcement tailwind that is stabilizing those volumes is not guaranteed to hold. The FDA’s May 2026 enforcement discretion policy will let manufacturers sell some vapes and nicotine pouches without a full license, a shift administration officials say could put 100 to 200 additional products on shelves within weeks.
Helix, Altria’s oral nicotine unit, is racing to build a buffer against that risk on a separate front. On! shipments grew 18% to more than 46 million cans in the quarter, and on! PLUS reached roughly 100,000 stores, representing 85% of nicotine pouch category volume, by quarter’s end.
Wall Street Rates Altria Stock a Hold With a $71 Mean Target
Analysts covering Altria stock split their ratings 4 buys, 7 holds, 1 underperform and 1 sell, and the 11 issuing formal price targets put the mean at $71, just below the stock’s current $72 price. That mean matches the median target exactly, while estimates range from a high of $82 to a low of $59. The tight gap between the mean and median suggests analysts broadly agree Altria stock has little room left before its next re-rating, even as the $82 high target hints at more conviction among the most bullish names on the list.
Wall Street Expects Altria Stock’s Normalized EPS Growth to Slow to 3% by Early 2027
Altria’s normalized EPS reached $1.32 in the first quarter of 2026, up 7.3% from a year earlier and the fastest quarterly growth rate in five quarters. Consensus expects that pace to cool. Normalized EPS grows to $1.50 in the second quarter, up 4%, and to $1.51 in the third quarter, up 4% again.
Growth is expected to hold near $1.37 in the fourth quarter, up 6%. It then slips to just 3% growth and $1.36 in the first quarter of 2027, before rebounding to 3% growth and $1.55 by the second quarter of 2027.
Whether that deceleration holds rests on a single threshold.
If the FDA’s enforcement discretion policy puts 100 to 200 new vape products on shelves before year-end, the cross-category moderation propping up Altria stock’s cigarette volumes, and its EPS trajectory, could reverse.
TIKR Values Altria Stock at $86, Pricing In Continued EPS Compounding
TIKR’s mid-case model values Altria stock at $86 by December 2030, implying a 20% total return from the current price of $72, or 4% annualized over the next 4.5 years.
That annualized return sits below the double-digit rates the broader market has delivered over full cycles, positioning Altria stock as an income-anchored compounder rather than a growth re-rating story.
The target is reachable because normalized EPS keeps compounding even as guidance points to a slower back half, and Marlboro’s premium share gains alongside Basic’s discount defense give the company multiple levers to protect that earnings base through 2027.
Should You Invest in Altria Group, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Altria Group, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Altria Group, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MO stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
